Morgan Stanley Put 90 NOVN 21.03..../ DE000MG45JA3 /
20/12/2024 17:20:29 | Chg.0.000 | Bid22:00:35 | Demandez à22:00:35 | Sous-jacent | Prix d'exercice | Date d'expiration | Type d'option |
---|---|---|---|---|---|---|---|
0.690EUR | 0.00% | - Bid taille: - |
- Ask la taille: - |
NOVARTIS N | 90.00 CHF | 21/03/2025 | Put |
GlobeNewswire
30/07
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
08/07
Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
GlobeNewswire
26/06
As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Co...
GlobeNewswire
13/06
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
GlobeNewswire
16/04
Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthriti...
GlobeNewswire
11/04
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Develo...
GlobeNewswire
14/03
IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
GlobeNewswire
28/02
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GlobeNewswire
28/02
PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invas...
GlobeNewswire
10/01
Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for S...
GlobeNewswire
05/01
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand ...
- La première page
- Retour
- 1
- 2
- 3
- 4
- Suivant
- La dernière page